XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $224K invested in XTL Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.49% → 0.49% (-0%)
40% less funds holding
Funds holding: 5 → 3 (-2)
45% less capital invested
Capital invested by funds: $405K → $224K (-$181K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
-$4K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$1.22K |
XTLB Hedge Fund Activity: Q3 2014 in Review
3 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2014, worth a combined $224K — down 45% from $405K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.04K. The largest seller was UBS, exiting entirely with an estimated $4K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2014, down from 5 in Q2 2014.
- Funds reported $224K of XTL Biopharmaceuticals stock for Q3 2014, down 45% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q3 2014 and 2 closed out, a net change of -2 holders.
- The largest XTL Biopharmaceuticals buyer in Q3 2014 was Tower Research Capital (TRC), an estimated $1.04K added.
- The largest XTL Biopharmaceuticals seller in Q3 2014 was UBS, an estimated $4K sold.
Based on aggregated 13F filings for Q3 2014.